The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
New Approvals Transform CLL Treatment, More Advances on the Horizon
February 25th 2015For additional insight on new agents and other emerging CLL therapies, OncLive spoke with Thomas Kipps, MD, PhD, professor of Medicine in the Division of Hematology-Oncology, and Deputy Director for Research at the UC San Diego Moores Cancer Center.
FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive Glioblastoma
February 23rd 2015Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.
First Direct-to-Consumer Genetic Test Gains FDA Approval
February 20th 2015The FDA has approved its first-ever direct-to-consumer genetic test for the detection of a gene variant that could be associated with Bloom syndrome, a rare inherited disorder associated with a higher risk of developing cancer and other health concerns.
Unprecedented OS Benefit Cements Pertuzumab Regimen as Frontline Standard in HER2-Positive MBC
February 20th 2015Frontline pertuzumab plus trastuzumab and docetaxel improved survival by nearly 16 months in metastatic HER2-positive breast cancer, according to results from the phase III CLEOPATRA study that are now published in The New England Journal of Medicine.
Researchers Highlight Ibrutinib Efficacy in Posttransplant, High-Risk CLL
February 18th 2015Ibrutinib (Imbruvica) showed promising activity in heavily pretreated, relapsed/refractory chronic lymphocytic leukemia after allogeneic stem cell transplantation, according to data presented at the American Society for Blood and Marrow Transplantation 2015 BMT Tandem Meeting.
Analysis Shows Increased Ovarian Cancer Risk From Hormone Replacement Therapy
February 17th 2015The risk of developing the two most common types of ovarian cancer significantly increases when taking hormone replacement therapy to alleviate symptoms of menopause, according to a meta-analysis of epidemiological studies.
ASCO Supports ACS Guidelines for Prostate Cancer Survivor Care
February 15th 2015ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer specialists and primary care physicians deliver high quality of care to patients with localized disease.
First Oral Proteasome Inhibitor Meets PFS Endpoint in Phase III Myeloma Trial
February 11th 2015The proteasome inhibitor ixazomib met its primary endpoint of improving progression-free survival at a prespecified interim analysis of a phase III trial of patients with relapsed/refractory multiple myeloma.
Sherman Says Lenvatinib Approval "Likely" as FDA Decision Date Nears
February 11th 2015With a deadline of April 14, the FDA will soon make its final approval decision on the oral multikinase inhibitor lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).